Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

12 agosto 2026 aggiornato da: Arjun Deb, MD

A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1

This is a Phase 1 single-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of AD-NP1, a humanized monoclonal antibody targeting human ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1). The study aims to assess the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AD-NP1 in healthy volunteers. Participants will be randomized to receive either AD-NP1 or placebo, with safety and efficacy monitored in accordance with Good Clinical Practice (GCP) guidelines. The study also seeks to explore changes in health-related quality of life (HRQOL) during the trial.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

36

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Los Angeles, California, Stati Uniti, 90095
        • UCLA Clinical and Translational Research Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Body weight ≤ 90kg
  • Ability to understand and the willingness to sign a written informed consent document
  • Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
  • Be in general good health without history of any of the conditions listed in exclusion criteria
  • No use of any tobacco products for at least 6 months
  • Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
  • Sexually active male subjects must use a barrier method of contraception during the study
  • Screening laboratory values must meet the following criteria:

    • WBC (>3,000 - <11,000/mm^3)
    • Platelets (>100,000/mm^3)
    • Hemoglobin (>10.5 gm/dl)
    • Creatinine (<1.1 x upper limit of normal [ULN])
    • BUN (<1.25 x ULN)
    • AST (<1.1 x ULN)
    • ALT (<1.1 x ULN)
    • Alkaline Phosphatase (<1.1 x ULN)
    • Bilirubin (<1.1 x ULN)
    • Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
  • Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
  • Weight > 90 kg
  • History of any of the following illnesses or conditions:
  • a. Respiratory condition (such as asthma requiring daily medication)
  • b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
  • c. Blood dyscrasias
  • d. Psychiatric disorder that precludes compliance with the clinical protocol
  • e. Hepatitis
  • Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
  • History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
  • History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
  • Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
  • Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
  • Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
  • Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
  • Currently breast-feeding
  • Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
  • Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparatore placebo: Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Sperimentale: Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparatore placebo: Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Sperimentale: Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparatore placebo: Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Sperimentale: Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparatore placebo: Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
Lasso di tempo: Day of infusion (Day 0) to 28 days post-dose
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Day of infusion (Day 0) to 28 days post-dose

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum Tolerated Dose of AD-NP1
Lasso di tempo: Day of infusion (Day 0) to 28 days post-dose
To be determined based on dose limiting toxicities (DLTs) and adverse events
Day of infusion (Day 0) to 28 days post-dose
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (pre-dose) up to Day 60 post-dose
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
Baseline (pre-dose) up to Day 60 post-dose
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (pre-dose) up to Day 60 post-dose
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
Baseline (pre-dose) up to Day 60 post-dose
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (pre-dose) up to Day 60 post-dose
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (pre-dose) up to Day 60 post-dose
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Plasma Uridine Concentration
Lasso di tempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Cytidine Concentration
Lasso di tempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Orotidine Concentration
Lasso di tempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Adenine Concentration
Lasso di tempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Carbamoyl Aspartate Concentration
Lasso di tempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Immunogenicity of a single IV dose of AD-NP1
Lasso di tempo: Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Determined by measuring levels of circulating anti-drug antibody in blood samples
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
Lasso di tempo: Baseline (pre-dose) up to Day 60 post-dose
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
Baseline (pre-dose) up to Day 60 post-dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 giugno 2026

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 maggio 2028

Date di iscrizione allo studio

Primo inviato

6 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 agosto 2026

Primo Inserito (Effettivo)

13 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 25-1584
  • PR250528 (Altro numero di sovvenzione/finanziamento: DOD-DEPARTMENT OF DEFENSE)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .